论文部分内容阅读
目的探讨中晚期非小细胞肺癌行同步放化疗联合靶向治疗的临床效果。方法选取2014年1月至2016年1月间泰州市第二人民医院收治的54例中晚期非小细胞肺癌患者,采用随机数表法分为观察组与对照组,每组27例,观察组患者采用同步放化疗联合靶向治疗,对照组患者采用单纯同步放化疗治疗,比较两组患者的功能状态(KPS)评分、治疗效果、不良反应及生活质量。结果治疗后,两组患者KPS评分与治疗前比较均明显升高,且观察组患者评分高于对照组,差异均有统计学意义(均P<0.05)。观察组患者治疗总有效率为81.5%,对照组为63.0%,两组比较,差异有统计学意义(P<0.05)。治疗过程中,观察组患者胃肠道反应和骨髓抑制发生率分别为14.8%和7.4%,均显著低于对照组的33.3%和55.6%,差异均有统计学意义(均P<0.05)。治疗后,观察组患者生活质量各项指标均显著高于对照组,两组比较,差异均有统计学意义(均P<0.05)。结论中晚期非小细胞肺癌行同步放化疗与靶向联合治疗效果显著,不良反应少,可提高患者生活质量。
Objective To investigate the clinical effect of concurrent chemoradiotherapy combined with targeted therapy in advanced non-small cell lung cancer. Methods 54 patients with advanced non-small cell lung cancer admitted to the Second People’s Hospital of Taizhou from January 2014 to January 2016 were randomly divided into observation group and control group using random number table method, with 27 cases in each group. The observation group The patients were treated with concurrent chemoradiotherapy combined with targeted therapy. Patients in the control group were treated with concurrent chemoradiotherapy. KPS scores, treatment effects, adverse reactions and quality of life were compared between the two groups. Results After treatment, the scores of KPS in both groups were significantly higher than those before treatment, and the score in observation group was higher than that in control group (all P <0.05). The total effective rate was 81.5% in observation group and 63.0% in control group, the difference was statistically significant (P <0.05). During the course of treatment, the incidences of gastrointestinal reactions and bone marrow suppression in the observation group were 14.8% and 7.4%, respectively, which were significantly lower than those in the control group (33.3% and 55.6%, both P <0.05). After treatment, the quality of life in the observation group were significantly higher than the control group, the difference was statistically significant (P <0.05). Conclusions The combination of concurrent chemoradiotherapy and targeted therapy is effective in the treatment of advanced non-small cell lung cancer with less adverse reactions and can improve the quality of life of patients.